LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

Search

CareDx Inc

Open

SectorGezondheidszorg

16.09 1.13

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

15.73

Max

16.82

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

12.117

106.172

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+37.67% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

39M

826M

Vorige openingsprijs

14.96

Vorige sluitingsprijs

16.09

Nieuwssentiment

By Acuity

17%

83%

20 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 nov 2025, 23:36 UTC

Populaire aandelen

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19 nov 2025, 22:13 UTC

Winsten
Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19 nov 2025, 21:55 UTC

Belangrijke Marktbewegers

Amgen Lung Cancer Drug Gets Full Approval From FDA

19 nov 2025, 21:43 UTC

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19 nov 2025, 23:55 UTC

Marktinformatie

Gold Rises on Possible Investment Demand -- Market Talk

19 nov 2025, 23:54 UTC

Marktinformatie

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19 nov 2025, 23:47 UTC

Winsten

Lenovo Group 2Q EPS $2.52 >0992.HK

19 nov 2025, 23:46 UTC

Winsten

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19 nov 2025, 23:45 UTC

Winsten

Lenovo Group 2Q Rev $20.5B >0992.HK

19 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19 nov 2025, 23:42 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 nov 2025, 23:41 UTC

Winsten

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19 nov 2025, 23:41 UTC

Winsten

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19 nov 2025, 23:40 UTC

Winsten

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19 nov 2025, 22:55 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19 nov 2025, 22:41 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19 nov 2025, 22:30 UTC

Acquisities, Fusies, Overnames

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19 nov 2025, 22:30 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19 nov 2025, 22:30 UTC

Acquisities, Fusies, Overnames

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19 nov 2025, 22:27 UTC

Acquisities, Fusies, Overnames

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19 nov 2025, 22:08 UTC

Winsten

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19 nov 2025, 22:00 UTC

Winsten

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19 nov 2025, 21:58 UTC

Winsten
Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19 nov 2025, 21:52 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

19 nov 2025, 21:49 UTC

Marktinformatie
Winsten

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19 nov 2025, 21:38 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19 nov 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35B

19 nov 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19 nov 2025, 21:24 UTC

Winsten
Acquisities, Fusies, Overnames

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

37.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22 USD  37.67%

Hoogste 22 USD

Laagste 22 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

20 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat